Friday, August 28, 2009

Cancer cure in tick saliva?

SAO PAULO - IT MAY be one of nature's repulsive little blood-sucking parasites, but the humble tick could yield a future cure for cancers of the skin, liver and pancreas, Brazilian researchers have discovered.

They have identified a protein in the saliva of a common South American tick, Amblyomma cajennense, that apparently reduces and can even eradicate cancerous cells while leaving healthy cells alone.

'This is a radical innovation,' said Ana Marisa Chudzinski-Tavassi, the molecular biologist at the Instituto Butantan in Sao Paulo who is leading the research.

'The component of the saliva of this tick could be the cure for cancer,' she told AFP.

She said she stumbled on the properties of the protein, called Factor X active, while testing the anti-coagulant properties of the tick's saliva - the way it stops blood thickening and clotting so the tick can keep gorging itself on its host.

The protein shares some characteristics with a common anti-coagulant called TFPI (Tissue Factor Pathway Inhibitor), specifically a Kunitz-type inhibitor which also has been shown to interfere with cell growth.

A theory that the protein might have an effect on cancerous cells led to laboratory tests on cell cultures - which exceeded all expectations.

'To our surprise it didn't kill normal cells, which were also tested,' Dr Chudzinski-Tavassi said. 'But it did kill the tumorous cells that were being analysed.' In her modest lab in the institute, housed in a rundown building, a line of immobile bloated ticks could be seen lined up with straws under their heads.

The small amounts of saliva captured that way was reproduced many times over in yeast vats so that tests could be carried out on lab rats with cancer.

The results have been more than promising.

'If I treat every day for 14 days an animal's tumour, a small tumour, this tumour doesn't develop - it even regresses. The tumour mass shrinks. If I treat for 42 days, you totally eliminate the tumour,' the scientist said -- AFP.

No comments: